Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
30/05/2025 11:13
Neoimmunetech Inc 950220.KQ: NEOIMMUNETECH: TO CONDUCT CAPITAL INCREASE OF 65 BILLION WON FOR OPERATIONAL FUNDS Source text: [ID:] Further company coverage: 950220.KQ
Recent news on Neoimmunetech
See all newsBrief: Tolerance Bio Licenses Clinical-Stage Long-Acting Interleukin-7 Therapy Efineptakin Alfa From Neoimmunetech
Brief: Emmaus Life Sciences Enters License And Distribution Agreement With Neoimmunetech
Brief: Neoimmunetech To Conduct Capital Increase Of 65 Billion Won For Operational Funds
Brief: FDA Grants Orphan Drug Designation Status To NeoImmuneTech's NT-I7 For Advanced Pancreatic Cancer Treatment
Brief: FDA Grants Orphan Drug Tag to NeoImmuneTech's Acute Radiation Syndrome Treatment